Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $12,000.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi acquired 10,000 shares of the stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $1.20 per share, with a total value of $12,000.00. Following the completion of the transaction, the chief executive officer now owns 137,553 shares of the company’s stock, valued at approximately $165,063.60. This represents a 7.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, December 18th, Krishna Vaddi purchased 100,000 shares of Prelude Therapeutics stock. The stock was purchased at an average price of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Trading Up 11.2 %

Shares of Prelude Therapeutics stock opened at $1.39 on Friday. The company has a fifty day simple moving average of $1.11 and a 200-day simple moving average of $2.98. Prelude Therapeutics Incorporated has a 12-month low of $0.80 and a 12-month high of $6.80. The stock has a market cap of $76.50 million, a price-to-earnings ratio of -0.78 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The firm had revenue of $3.00 million for the quarter. On average, analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $4.00 price objective (down from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a report on Friday, November 8th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PRLD. Barclays PLC grew its position in shares of Prelude Therapeutics by 86.0% during the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after acquiring an additional 12,564 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Prelude Therapeutics by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after purchasing an additional 14,226 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Prelude Therapeutics by 103.2% in the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after buying an additional 14,769 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after buying an additional 15,682 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Prelude Therapeutics by 8.2% during the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after buying an additional 29,765 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.